Estrella Immunopharma, Inc. (ESLAW) Financials
ESLAW Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 1.8 million | 9.3 million |
| March 31, 2026 | 3.7 million | 8.9 million |
| Dec. 31, 2025 | 3.2 million | 13.5 million |
| Sept. 30, 2025 | 3.5 million | 13.4 million |
ESLAW Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -1.8 million | 145298 |
| March 31, 2026 | -6.7 million | 146714 |
| Dec. 31, 2025 | -177487 | 148360 |
| Sept. 30, 2025 | -727332 | 152421 |
ESLAW Net Income
No data available :(
ESLAW Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 146670 | - | - |
| March 31, 2026 | 1.9 million | - | - |
| Dec. 31, 2025 | 1.4 million | - | - |
| Sept. 30, 2025 | 1.6 million | - | 4000 |
ESLAW Shares Outstanding
ESLAW Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | - | 1.4 million | 684015 | - |
| March 31, 2026 | - | 1.4 million | 891789 | - |
| Dec. 31, 2025 | - | 25414 | 587785 | - |
| Sept. 30, 2025 | - | 4.2 million | 648507 | - |
ESLAW Cost of Revenue
No data available :(
ESLAW
Price: $0.06
52 week price:
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Market Capitalization: 22.2 million